Mandate

Vinge advises IRLAB Therapeutics in connection with a directed share issue

May 24, 2018

The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby IRLAB Therapeutics will raise proceeds of SEK 138,6 million, before issue costs.

The share issue is directed to a number of selected institutional investors in Sweden and the US. 
 
IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.
 
Vinge’s team has consisted of Dain Hård Nevonen, Sofie Bjärtun and Hampus Olsson
 
 

Vinge employs additional antitrust economists to further strengthen its practice

We welcome Adam Löfquist and Carl Widstrand to our EU, Competition & Regulatory practice group.
September 30, 2021

European Commission provides sanctions compliance guidance

The European Commission has recently issued three opinions regarding the interpretation of asset freeze provisions in certain sanctions legislation pertaining to Central African Republic, Ukraine, Libya and Syria. The opinions are also of relevance for other sanctions regimes which provide for the same or similar restrictions. Therefore, their practical relevance goes far beyond the sanctions regimes in the context of which they were issued and they therefore provide for helpful guidance regarding the required thresholds for sanctions compliance generally.
September 20, 2021

Vinge contributing to International Comparative Legal Guides

Vinge’s specialists within Maritime and Transport law have been requested to contribute with a chapter explaining the Swedish legislative framework in relation to maritime law in the International Comparative Legal Guides, ICLG.
August 20, 2021